Another approach to targeting PKC involves the use of antisense oligonucleotides, which can selectively reduce the expression levels of PKC isoforms implicated in cancer cell proliferation, apoptosis and distinctive signaling pathways. This evidence concerns the gene PRRT2 and cancer.